Use of a small molecule inhibitor in the preparation of a product for combating ebola virus infection

By using the acetyl-CoA carboxylase-α (ACCA) allosteric inhibitor TOFA, the expression of the Ebola virus VP40 gene and protein was inhibited, solving the problem of poor efficacy of existing drugs in the treatment of Ebola virus infection and achieving a highly efficient and safe virus inhibition effect.

CN120694986BActive Publication Date: 2026-05-29SUN YAT SEN UNIVERSITY SHENZHEN +1
2 Cites 0 Cited by

Patent Information

Application Number
CN202510957701.2
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2025-07-11
Publication Date
2026-05-29
Estimated Expiration
2045-07-11

AI Technical Summary

Technical Problem

Existing monoclonal antibody drugs have limited effectiveness in treating Ebola virus infection, and their large molecular weight makes it difficult to penetrate the immune protection zone where the virus persists, resulting in poor treatment efficacy and potential risks of transmission and sequelae.

Method used

The acetyl-CoA carboxylase-α (ACCA) allosteric inhibitor TOFA was used. The small molecule inhibitor TOFA can inhibit the expression of the Ebola virus VP40 gene and protein, thereby blocking viral replication and infection.

Benefits of technology

TOFA exhibits significant antiviral activity at low concentrations, with low cytotoxicity. It effectively inhibits the replication and protein expression of Ebola pseudovirus, providing a novel candidate drug for the treatment of Ebola virus infection, and has a high safety profile.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The application discloses application of a small molecule inhibitor in preparation of an anti-Ebola virus infection product. The application firstly confirms the anti-Ebola virus capability of TOFA, and the cell toxicity of TOFA is small (CC50 value is 7.717 muM), and TOFA can effectively inhibit replication of Ebola pseudovirus at a low concentration (IC50 value is 1.976 muM), so that a new candidate small molecule compound for developing a novel anti-Ebola virus infection drug is provided, a new technical selection for effectively preventing a severe infectious disease is provided, and the application has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art